International Neoantigen Summit SCIENCE on July 21-23, 2026 in Amsterdam, Netherlands

The neoantigen-targeted therapies industry is thawing and coming out of its biotech winter fuelled by Moderna’s recent news showing 49% decrease in disease progression after 5 years. This momentum has reignited confidence across pharma and biotech, accelerating a neoantigen programme and pushing more candidates into the clinic than ever before.

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches - this is your only platform dedicated to sharing critical developments in neoantigen therapies.

In a unique position to unite all the key players in the neoantigen industry, including the likes of Nykode Therapeutics, Evaxion, Geneos and more, this summit sits at the heart of the neoantigen industry, making every conversation relevant and every connection intentional.

Attend your only annual checkpoint to access the latest clinical updates, uncover breakthrough innovations and form partnerships that will drive the next wave of neoantigen-targeted therapies forward.

URLs:
Tickets: https://go.evvnt.com/3552745-2?pid=10008
Brochure: https://go.evvnt.com/3552745-3?pid=10008

Time: 7:00 AM - 4:10 PM

Venue Details: Park Plaza Victoria Amsterdam, 1-5 Damrak, Amsterdam, Noord-Holland, 1012 TM, Netherlands

Category: Conferences

Prices:

Conference + Workshop Day - Drug Developer: EUR 3997.00,

Conference Only - Drug Developer: EUR 2899.00,

Conference + Workshop Day - Academic: EUR 3297.00,

Conference Only - Academic: EUR 2499.00,

Conference + Workshop Day - Service Provider: EUR 4797.00,

Conference Only - Service Provider: EUR 3499.00

Speakers: Ken Carter, Chairman, Black Canyon Bio, Dirk Hadaschik, Chief Scientific Officer, Cecava, Fernando Kreutz, Founder and Chief Executive Officer, CellVax Therapeutics, Jason Barbour, Chief Executive Officer, Echo Immune, Jon Moore, Chief Scientific Officer, Epitopea Ltd, Casper WF van Eijck, Technical Physician and Principal Investigator, Erasmus MC, Koen Bezemer, General Manager, Erasmus MC, Alfred Slanetz, President and Chief Executive Officer, Geneius, Ildiko Csiki, Chief Medical Officer, Geneos Therapeutics, Beryl Whitman, Founder and Chief Executive Officer, Khosen Bio, Pouya Faridi, Lead Investigator, Translational Antigen Discovery Laboratory, Co-Director, Monash Proteomics and Metabolomics Platform, Monash University and Hudson Institute of Medical Research, Luigi Notari, Senior Scientist Neoatnigen Production and Development, NeoGap Therapeutics, Heather Shaw, Consultant Medical Oncologist, NHS, Elisa Scarselli, Chief Scientific Officer, Nouscom, Brian Weinert, Director, Nykode Therapeutics, Darshit Shah, Senior Scientist, Regeneron, Benoit Grellier, Senior Bioinformatician, Head of BioIT Department, Transgene, Maurizio Ceppi, Chief Scientific Officer, Transgene, Eniko Toke, Chief Scientific Officer, Treos Bio, Anna-Dorothea Gorki, Chief Scientific Officer, YGION Biomedical